Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial

医学 肝硬化 意向治疗分析 肝移植 随机对照试验 门脉高压 内科学 人口 外科 经颈静脉肝内门体分流术 胃肠病学 移植 环境卫生
作者
Yong Lv,Zhiping Yang,Lei Liu,Kai Li,Chuangye He,Zhenyu Wang,Wei Bai,Wengang Guo,Tianlei Yu,Xulong Yuan,Hongbo Zhang,Huahong Xie,Liping Yao,Jianhong Wang,Tao Li,Qiuhe Wang,Hui Chen,Enxin Wang,Dongdong Xia,Bohan Luo
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (8): 587-598 被引量:217
标识
DOI:10.1016/s2468-1253(19)30090-1
摘要

Background The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding. Methods We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed. Findings From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25–0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97–100) in the early TIPS group compared with 84% (75–96; absolute risk difference 15% [95% CI 5–48]; p=0·02) and at 1 year was 86% (79–94) in the early TIPS group versus 73% (62–88) in the control group (absolute risk difference 13% [95% CI 2–28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups. Interpretation Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. Funding National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张贵川完成签到,获得积分10
1秒前
小二郎应助南方白芝麻胡采纳,获得10
1秒前
LZ完成签到,获得积分20
1秒前
沅沅发布了新的文献求助10
2秒前
忧郁小白菜完成签到,获得积分20
2秒前
3秒前
3秒前
4秒前
希望天下0贩的0应助小飞采纳,获得10
4秒前
4秒前
LLL完成签到,获得积分10
4秒前
5秒前
汉堡包应助nietongle采纳,获得10
6秒前
GsunW完成签到,获得积分10
6秒前
6秒前
NexusExplorer应助zgnh采纳,获得10
6秒前
6秒前
7秒前
斯文败类应助tayyy采纳,获得10
7秒前
7秒前
7秒前
Winston完成签到,获得积分10
7秒前
8秒前
东方羽之佳完成签到,获得积分10
8秒前
量子星尘发布了新的文献求助10
9秒前
大方蜡烛发布了新的文献求助10
9秒前
专注夏寒完成签到,获得积分10
9秒前
南方白芝麻胡完成签到,获得积分10
9秒前
姚玲完成签到,获得积分10
10秒前
厚德载物完成签到,获得积分10
11秒前
兰粥拉面应助无心的安青采纳,获得10
11秒前
11秒前
小李发布了新的文献求助10
11秒前
顾矜应助leekk采纳,获得10
12秒前
Qinghen发布了新的文献求助10
13秒前
刘shuchang发布了新的文献求助10
13秒前
英吉利25发布了新的文献求助30
13秒前
14秒前
Loong完成签到,获得积分10
14秒前
喜悦幻巧完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introduction to Early Childhood Education 1000
2025-2031年中国兽用抗生素行业发展深度调研与未来趋势报告 1000
List of 1,091 Public Pension Profiles by Region 921
Identifying dimensions of interest to support learning in disengaged students: the MINE project 800
Synthesis and properties of compounds of the type A (III) B2 (VI) X4 (VI), A (III) B4 (V) X7 (VI), and A3 (III) B4 (V) X9 (VI) 500
Antihistamine substances. XXII; Synthetic antispasmodics. IV. Basic ethers derived from aliphatic carbinols and α-substituted benzyl alcohols 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5429316
求助须知:如何正确求助?哪些是违规求助? 4542743
关于积分的说明 14182778
捐赠科研通 4460720
什么是DOI,文献DOI怎么找? 2445823
邀请新用户注册赠送积分活动 1437000
关于科研通互助平台的介绍 1414164